The 2025/26 Keystone Meeting “The Ubiquitin Family in Biology and Disease” will bring together researchers from the broad areas of ubiquitin biology and ubiquitin-like proteins and connect them to scientists actively working on exploiting these posttranslational modifications for therapeutic benefit. Topics of particular interest will be novel ubiquitin-dependent signaling pathways that play roles in disease and are amenable to small-molecule intervention; new functions of ubiquitin-like proteins, such as those providing ribosomal quality control; the study of catalytic mechanisms of ubiquitylation enzymes and their implications for drug discovery; and exploiting ubiquitylation enzymes for novel induced proximity therapies. Just as basic biology continues to inform drug discovery, clinical trials have recently shed light on the cellular function of ubiquitylation enzymes and their targets. Building a tightly knit community that includes scientists from both discovery and translational ubiquitin biology is critical for discovering new biology and developing new induced proximity modalities that will benefit patients in decades to come. Thus, this meeting will highlight interdisciplinary science with an emphasis on disease treatment. As interdisciplinary science often requires increased focus on effective communication, this meeting will include workshops that expand interactions between academic and biotech scientists through career roundtables, meet the editors, or drug discovery workshops.